Oasmia Pharmaceutical

Selected news for the company - Oasmia Pharmaceutical, collected since 5/2019. Recent stories appear in nysenewstimes.com. This company shares news with Julian Aleksov, Bragar Eagel, Phillip Kim and many others.

Please provide a valid email address.
Shares Healthcare News With (link):
Healthcare Topics
Companies
Capital Firms
People

Selected Headlines

Date Headline (link) Source Relevant Snippet
5/10/2021 Alveolar Rhabdomyosarcoma Treatment Market Substantial Growth in the Upcoming years and Forecast 2020-2027 nysenewstimes.com ... competitive advantage over others operating in the same space.The main key players in the industry are Eli Lilly and Company, GlaxoSmithKline Plc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Oasmia Pharmaceutical , Celgene Corporation, Pfizer, Inc., and Johnson & Johnson Services, Inc.Get Request Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1552Important features during the offer and main features of the report:1) What does all ...
5/10/2021 Pet Cancer Therapeutics Market Will Observe a Phenomenal Growth and Forecast 2020-2027 nysenewstimes.com ... in the same space.The main key players in the industry are Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, Oasmia Pharmaceutical s AB, and Zoetis.Get Request Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1284Important features during the offer and main features of the report:1) What does all the regional segmentation cover? Can the ...
4/30/2021 Estrogen Receptor Beta Global Market 2019 Research Report by – Acadia Pharmaceuticals Inc, AstraZeneca Plc, Atossa Genetics Inc, Chamaeleo Pharma NV ccguardian.com ... market are : Acadia Pharmaceuticals Inc , AstraZeneca Plc , Atossa Genetics Inc , Chamaeleo Pharma NV , Eli Lilly and Company , Endece LLC , EndoCeutics Inc , Karo Pharma AB , Kissei Pharmaceutical Co Ltd , MEI Pharma Inc , Mithra Pharmaceuticals SA , Oasmia Pharmaceutical AB , ,The report covers all the region, which shows the regional development status and market size. the Estrogen Receptor Beta industry regional analysis includes the region like United States, Europe, China, Japan, Southeast Asia ...
4/26/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Upgraded to “Buy” at Zacks Investment Research dispatchtribunal.com US Crude Prices Plummet 4% as Russia and OPEC Consider Easing CapsZacks Investment Research upgraded shares of Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) from a hold rating to a buy rating in a research note published on Thursday morning, Zacks.com reports. The brokerage currently has $1.25 price objective on the stock.According to Zacks, “Oasmia Pharmaceutical AB is a pharmaceutical company which develops and manufactures drugs for human and ...
4/26/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Upgraded to Buy by Zacks Investment Research theenterpriseleader.com Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Upgraded to Buy by Zacks Investment Research Posted by Liza Goodheart on Apr 26th, 2021Zacks Investment Research upgraded shares of Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) from a hold rating to a buy rating in a research report report published on Thursday, Zacks.com reports. They currently have $1.25 price objective on the stock.According to Zacks, “Oasmia Pharmaceutical AB is a pharmaceutical company ...
4/25/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Stock Rating Upgraded by Zacks Investment Research thelincolnianonline.com Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Stock Rating Upgraded by Zacks Investment Research Posted by Paula Ricardo on Apr 25th, 2021 TweetZacks Investment Research upgraded shares of Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) from a hold rating to a buy rating in a research note published on Thursday, Zacks.com reports. The brokerage currently has $1.25 price target on the stock.According to Zacks, “Oasmia Pharmaceutical AB is a pharmaceutical ...
4/24/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Stock Rating Upgraded by Zacks Investment Research zolmax.com ... oncology. Its drugs portfolio comprises Paclical, Doxophos, Docecal and OAS-19, for human treatment as well as Paccal Vet-CA1 and Doxophos Vet, for cancer treatment in dogs, which are in different clinical phases. Oasmia Pharmaceutical AB is based in Uppsala, Sweden. “ Get Oasmia Pharmaceutical AB (publ) alerts:Shares of Oasmia Pharmaceutical AB (publ) stock opened at $1.23 on Thursday. Oasmia Pharmaceutical AB has a 1 year low of ...
4/24/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Lowered to “Hold” at Zacks Investment Research Daily Political Zacks Investment Research downgraded shares of Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) from a buy rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks, “Oasmia Pharmaceutical AB is a pharmaceutical company which develops and manufactures drugs for human and veterinary oncology. Its drugs portfolio comprises Paclical, Doxophos, Docecal and OAS-19, for human treatment as well as Paccal Vet-CA1 ...
4/24/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Stock Rating Lowered by Zacks Investment Research thelincolnianonline.com Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Stock Rating Lowered by Zacks Investment Research Posted by Donna Armstrong on Apr 24th, 2021 TweetZacks Investment Research cut shares of Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) from a buy rating to a hold rating in a research note issued to investors on Tuesday, Zacks.com reports.According to Zacks, “Oasmia Pharmaceutical AB is a pharmaceutical company which develops and manufactures drugs for human ...
4/24/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Rating Increased to Buy at Zacks Investment Research wkrb13.com ... oncology. Its drugs portfolio comprises Paclical, Doxophos, Docecal and OAS-19, for human treatment as well as Paccal Vet-CA1 and Doxophos Vet, for cancer treatment in dogs, which are in different clinical phases. Oasmia Pharmaceutical AB is based in Uppsala, Sweden. “Get Oasmia Pharmaceutical AB (publ) alerts: OTCMKTS:OASMY opened at $1.23 on Thursday. Oasmia Pharmaceutical AB has a fifty-two week low of $1.09 and a fifty ...
4/23/2021 Zacks Investment Research Lowers Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) to Hold - WKRB News wkrb13.com Zacks Investment Research lowered shares of Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) from a buy rating to a hold rating in a research note issued to investors on Tuesday, Zacks.com reports.According to Zacks, “Oasmia Pharmaceutical AB is a pharmaceutical company which develops and manufactures drugs for human and veterinary oncology. Its drugs portfolio comprises Paclical, Doxophos, Docecal and OAS-19, for human treatment as well as Paccal Vet-CA1 ...
4/23/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Upgraded to Buy by Zacks Investment Research baseballnewssource.com Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Upgraded to Buy by Zacks Investment Research Posted by Andrew WalzZacks Investment Research upgraded shares of Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) from a hold rating to a buy rating in a report issued on Thursday morning, Zacks.com reports. The firm currently has $1.25 target price on the stock.According to Zacks, “Oasmia Pharmaceutical AB is a pharmaceutical company which develops and manufactures ...
4/23/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Raised to “Buy” at Zacks Investment Research - Transcript Daily transcriptdaily.com ... oncology. Its drugs portfolio comprises Paclical, Doxophos, Docecal and OAS-19, for human treatment as well as Paccal Vet-CA1 and Doxophos Vet, for cancer treatment in dogs, which are in different clinical phases. Oasmia Pharmaceutical AB is based in Uppsala, Sweden. “Get Oasmia Pharmaceutical AB (publ) alerts: OASMY traded up $0.04 during trading on Thursday, reaching $1.19. The company had a trading volume of 610 shares, compared to ...
4/23/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Raised to “Buy” at Zacks Investment Research - Stock Observer thestockobserver.com ... oncology. Its drugs portfolio comprises Paclical, Doxophos, Docecal and OAS-19, for human treatment as well as Paccal Vet-CA1 and Doxophos Vet, for cancer treatment in dogs, which are in different clinical phases. Oasmia Pharmaceutical AB is based in Uppsala, Sweden. “Get Oasmia Pharmaceutical AB (publ) alerts: Shares of OASMY traded up $0.04 during trading hours on Thursday, hitting $1.19. 610 shares of the stock traded hands, compared ...
4/22/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Downgraded by Zacks Investment Research baseballnewssource.com ... oncology. Its drugs portfolio comprises Paclical, Doxophos, Docecal and OAS-19, for human treatment as well as Paccal Vet-CA1 and Doxophos Vet, for cancer treatment in dogs, which are in different clinical phases. Oasmia Pharmaceutical AB is based in Uppsala, Sweden. “ Get Oasmia Pharmaceutical AB (publ) alerts:OTCMKTS:OASMY opened at $1.15 on Tuesday. The company has a current ratio of 2.33, a quick ratio of 2.08 and ...
4/21/2021 Kazia Therapeutics completes third licensing deal in seven weeks MSN ... to its potential brain candidate drug to Simcere Pharmaceutical Group on March 29 for an upfront payment $US11 million ($14.2 million), and on March 1 licensing its ovarian cancer drug candidate to Sweden-based Oasmia Pharmaceutical s for $US4 million. The spate of deals would be unusual for a company many times Kazia’s size, CEO Dr James Garner says, but the company is executing on its unusual business model of ...
4/21/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Rating Lowered to Hold at Zacks Investment Research slatersentinel.com Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Rating Lowered to Hold at Zacks Investment Research Posted by Trina Covell on Apr 21st, 2021Zacks Investment Research downgraded shares of Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) from a buy rating to a hold rating in a research note published on Tuesday morning, Zacks.com reports.According to Zacks, “Oasmia Pharmaceutical AB is a pharmaceutical company which develops and manufactures drugs for human and ...
4/21/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Downgraded to “Hold” at Zacks Investment Research Mayfield Recorder Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Downgraded to “Hold” at Zacks Investment Research Posted by Charles Blunt on Apr 21st, 2021Zacks Investment Research cut shares of Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) from a buy rating to a hold rating in a report issued on Tuesday, Zacks.com reports.According to Zacks, “Oasmia Pharmaceutical AB is a pharmaceutical company which develops and manufactures drugs for human and veterinary oncology ...
4/20/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Downgraded by Zacks Investment Research to “Hold” Ticker Report ... oncology. Its drugs portfolio comprises Paclical, Doxophos, Docecal and OAS-19, for human treatment as well as Paccal Vet-CA1 and Doxophos Vet, for cancer treatment in dogs, which are in different clinical phases. Oasmia Pharmaceutical AB is based in Uppsala, Sweden. “Get Oasmia Pharmaceutical AB (publ) alerts: OASMY stock opened at $1.20 on Tuesday. Oasmia Pharmaceutical AB has a 52 week low of $1.09 and a 52 week ...
3/13/2021 Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) Stock Price Down 2.4% dispatchtribunal.com US Crude Prices Plummet 4% as Russia and OPEC Consider Easing CapsShares of Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) dropped 2.4% during trading on Thursday . The stock traded as low as $1.14 and last traded at $1.14. Approximately 141 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 3,797 shares. The stock had previously closed at $1.17.Separately, Zacks Investment Research ...